{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:41:37Z","timestamp":1773279697827,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.10.029","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T12:29:40Z","timestamp":1639484980000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5073-8829","authenticated-orcid":false,"given":"Philipp","family":"Thelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-6386","authenticated-orcid":false,"given":"Anne Santerre","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-7256","authenticated-orcid":false,"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-5780","authenticated-orcid":false,"given":"Axel","family":"Hamprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.029_bib0001","first-page":"345","article-title":"Treatment options for carbapenem-resistant Gram-negative infections","volume":"115","author":"Fritzenwanker","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jgar.2021.10.029_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijmm.2016.05.009","article-title":"Multicentre investigation of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in German hospitals","volume":"306","author":"Kaase","year":"2016","journal-title":"Int J Med Microbiol"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.10.029_bib0003","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0004","unstructured":"European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. ECDC; 2019. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018 [accessed 24 December 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105959","article-title":"German Carbapenem Resistance Study Group. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane\u2013tazobactam in Germany","volume":"55","author":"Kresken","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.10.029_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.10.029_bib0008","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2021.10.029_bib0009","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile \u03b2-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.10.029_bib0010","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3389\/fmicb.2019.02509","article-title":"Pathogenicity of clinical OXA-48 isolates and impact of the OXA-48 IncL plasmid on virulence and bacterial fitness","volume":"10","author":"Hamprecht","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.10.029_bib0011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00063-017-0272-2","article-title":"Development of antimicrobial resistance in Germany: what is the current situation? [in German]","volume":"112","author":"Maechler","year":"2017","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"10.1016\/j.jgar.2021.10.029_bib0012","first-page":"421","article-title":"Nosocomial infections and infections with multidrug-resistant pathogens\u2014frequency and mortality [in German]","volume":"141","author":"Gastmeier","year":"2016","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jgar.2021.10.029_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195757","article-title":"Carbapenem-resistant Gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"13","author":"Katchanov","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.029_bib0014","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections","volume":"20","author":"Papp-Wallace","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2021.10.029_bib0015","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","article-title":"Analysis of the clinical antibacterial and antituberculosis pipeline","volume":"19","author":"Theuretzbacher","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.10.029_bib0016","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.10.029_bib0017","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0018","unstructured":"Shionogi B.V.Fetcroja (cefiderocol) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf [accessed August 2020]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0019","unstructured":"Shionogi Inc. Fetroja (cefiderocol) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209445s002lbl.pdf [accessed January 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0020","first-page":"e01454","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.029_bib0021","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.029_bib0022","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.50.1900734","article-title":"Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019","volume":"24","author":"Haller","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.10.029_bib0023","unstructured":"International Organization for Standardization (ISO). ISO 20776-1:2006: Clinical laboratory testing and in vitro diagnostic test systems\u2014Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO; 2006. https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:20776:-1:ed-1:v1:en [accessed 24 December 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0024","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf [accessed January 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0025","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoints for cefiderocol from EUCAST: Addendum May 2020 to EUCAST breakpoint tables version 10.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Cefiderocol_addendum_20200501.pdf [accessed January 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.10.029_bib0027","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0028","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000092","article-title":"Ceftolozane\u2013tazobactam- and ceftazidime\u2013avibactam-resistant Pseudomonas aeruginosa mastoiditis","volume":"2","author":"Jacobs","year":"2020","journal-title":"Access Microbiol."},{"key":"10.1016\/j.jgar.2021.10.029_bib0029","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1089\/mdr.2019.0298","article-title":"Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City","volume":"26","author":"Iregui","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2021.10.029_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","author":"Wagenlehner","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.029_bib0031","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.10.029_bib0032","unstructured":"US Food and Drug Administration (FDA). Cefiderocol injection. FDA identified breakpoints. FDA; 2020. https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection [accessed 7 April 2021]."},{"key":"10.1016\/j.jgar.2021.10.029_bib0033","doi-asserted-by":"crossref","first-page":"e01649","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution","volume":"59","author":"Morris","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.10.029_bib0034","doi-asserted-by":"crossref","first-page":"e01391","DOI":"10.1128\/AAC.01391-17","article-title":"Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis","volume":"62","author":"Kawaguchi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.029_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0974-777X.121996","article-title":"Nonfermenting Gram-negative bacilli other than Pseudomonas aeruginosa and Acinetobacter spp. causing respiratory tract infections in a tertiary care center","volume":"5","author":"Chawla","year":"2013","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0036","first-page":"887","article-title":"Emerging trends of bloodstream infections: a six-year study at a paediatric tertiary care hospital in Kabul","volume":"26","author":"Tariq","year":"2016","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jgar.2021.10.029_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007729","article-title":"Identification of Gram negative non-fermentative bacteria: how hard can it be?","volume":"13","author":"Whistler","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.10.029_bib0038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.33314\/jnhrc.v19i1.3240","article-title":"Carbapenem resistance in non-fermentative Gram-negative bacilli isolated from intensive care unit patients of a referral hospital","volume":"19","author":"Yadav","year":"2021","journal-title":"J Nepal Health Res Counc"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:55Z","timestamp":1761991135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"alternative-id":["S2213716521002733"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.029","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}